The drug registration process in China typically takes 12 to 18 months. This includes preclinical studies, dossier review, and regulatory review by the National Medical Products Administration (NMPA). Timelines can vary based on the drug’s complexity, whether a China local clinical study is needed, and the completeness of the submitted data.
